Mineralys Therapeutics Bolsa (NASDAQ: MLYS)

Últimas noticias sobre Mineralys Therapeutics (NASDAQ:MLYS) Bolsa

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

JP Morgan analyst Ken Goldman maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Neutral and lowers the price target from $102 to $91.

Price Target

Analyst Ratings

FRPT

JP Morgan Maintains Neutral on Freshpet, Lowers Price Target to $91

JP Morgan analyst Anthony Paolone maintains Cushman &amp; Wakefield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) with a Neutral and lowers the price target from $17 to $14.

JP Morgan Maintains Neutral on Cushman & Wakefield, Lowers Price Target to $14

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>AAPL</li>
<li>DJT</li>
<li>QQQ</li>
<li>GLD</li>
<li>AMZN</li>
<li>MAGA</li>
<li>T</li>
<li>COAL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

AMZN

COAL

MAGA

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of April 10, 2025 (Via Swaggy Stocks)

Ordinarily, during a market decline like the one we have seen since the tariff announcements on Wednesday afternoon—where the market has dropped ten percent in just a couple of days and opened significantly lower on Monday—we would expect to see a wave of insider buying.
A selloff of this magnitude would typically be a siren call for executives and directors to bring out the checkbooks. However, that has not happened. Not even close.
When you stop and think about it, the lack of insider buying is not all that surprising. The market, even after the hit, still is not cheap, not by any meaningful valuation or earnings metric.
On a trailing twelve-month basis, we are trading at 24 times earnings. Yes, that is off the recent high of almost 30 but it is still well above historical norms. Even when examining projected earnings, valuations remain elevated.
The Shiller CAPE ratio, the inflation-adjusted ten-year earnings metric that is one of the best long-term valuation tools available, is sitting at 31. That figure is down from a recent peak near 35, yet it remains significantly higher than the long-run average.
The market is not cheap.
It is certainly not inexpensive enough to inspire the kind of aggressive insider buying we usually observe when stocks experience a sharp decline. However, the situation extends beyond high price-to-earnings ratios.
The real concern here is uncertainty. Massive, unquantifiable, policy-driven uncertainty.
This is not a typical earnings miss, or a selloff triggered by a surprise from the Federal Reserve. This is a geopolitical disruption, triggered by the Trump administration&#8217;s implementation of punitive tariffs, a policy that is not being welcomed by global markets.
Rhetoric continues to escalate. Both sides keep increasing the stakes, threatening a full-blown trade war with no clear resolution in sight.
Executives who are seeing their stock prices fall ten, fifteen, or even twenty percent year-to-date would normally feel the urge to start buying. However, that instinct is being overridden by fear.
Will there be a recession? Will inflation take hold? Could we face both? Might stagflation emerge? Could the tariff tit-for-tat spiral into a scenario as damaging as the 1930 Smoot-Hawley debacle, which severely disrupted global trade and exacerbated the Great Depression?
There are no clear answers. When clarity is absent, insiders hesitate. They are not making purchases because they simply lack visibility. There is no certainty about how this situation will impact their businesses or the broader economy. As a result, they wait.
There is one segment of the market that is showing a different trend over the past few days: the closed-end fund market.
I have had a deep appreciation for this space since the late 1980s, when we were dealing with the aftermath of Drexel Burnham and the collapse of the junk bond market.
Junk bonds rose to prominence in the 1980s, driven by Michael Milken and his team at Drexel. These instruments funded takeovers, corporate expansions, and startups such as MCI. Even the infamous RJR Nabisco deal was partially financed by junk bonds. Eventually, the market collapsed. Many of these bonds suffered significant losses.
By the late 1980s, it became evident that many of these so-called junk bonds were still performing well—generating yields of ten, eleven, twelve, thirteen, even fourteen percent. That level of income caught investors&#8217; attention. Major investment firms such as Putnam, Dean Witter, Pioneer, and others began launching closed-end funds comprised of these bonds.
Closed-end funds are well-suited for environments like this. Unlike traditional mutual funds, they do not issue or redeem shares daily. An IPO raises the capital, and that is it. Shares trade on an exchange, and the number of shares remains fixed.
Closed-end funds are subject to the same psychological swings as the rest of the market. Popular funds will trade for more than the value of the stocks and bonds owned by the funds. Unpopular or neglected funds will often trade at a discount to the value of their holdings.
When the junk bond markets collapsed, we were buying funds at 20% less than the market value of the bonds they owned and yielding north of 15%.
I have been a buyer of discounted closed-end funds ever since with outstanding results. Discounts tend to revert to the mean over time.
The CEO of one closed-end fund decided that he would add to his stake in the fund he helps oversee during last week&#8217;s carnage.
The Kayne Anderson MLP/Midstream Fund (Ticker: KYN) invests in energy infrastructure assets. Most MLPs own what are known as midstream infrastructure assets. This includes things like pipelines, gathering facilities, and shipping terminals.
The Kayne Anderson MLP fund owns almost all the major players in the North American midstream market. When you own this fund, you own almost every asset involved in moving oil and gas from the field to the refinery to the end destination.
The fund is currently trading at a discount to the value of its assets of about 12.5% and yielding north of 8%.
James Baker, the president and CEO of the fund, likes what he sees. Last week as all things energy were being sold, he stepped up and bought $479,000 worth of shares.
In spite of the green energy pipe dreams, oil and gas demand is still growing and will continue to do so.
As it moves from here to there, we will collect a fee that is paid out as a dividend.
Over time we should see the value of the assets we own increase, giving us a huge total return.

Opinion

Alpha Buying: This 8% Yield Fund Just Got a CEO-Sized Endorsement

JP Morgan analyst Anthony Paolone maintains Colliers International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGI#NASDAQ">CIGI</a>) with a Neutral and lowers the price target from $167 to $142.

CIGI

JP Morgan Maintains Neutral on Colliers International Gr, Lowers Price Target to $142

<a href="https://www.dallasfed.org/news/speeches/logan/2025/lkl250410" title="https://www.dallasfed.org/news/speeches/logan/2025/lkl250410">https://www.dallasfed.org/news/speeches/logan/2025/lkl250410</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Logan Says Sustained Burst Of Inflation Could Lead To Rise In Inflation Expectations; Inflation Persistence Will Depend On How Quickly Companies Pass Through Cost Increases, And If Long-term Inflation Expectations Remain Well Anchored

Fed's Logan Says Important To Keep Any Tariff-related Price Increases From Fostering More Persistent Inflation; If Higher Inflation Expectations Get Entrenched, Road To Price Stability Is Longer, Economic Scars Are Deeper; For Now, Stance Of Fed Policy Is Well Positioned; Financial Markets Have Been Volatile; Higher-than-expected Tariffs Would Very Likely Raise Both Unemployment And Inflation

Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), the media venture of President Donald Trump, has announced its expansion into Canada and Mexico. The company&#8217;s&nbsp;Truth Social platform and Truth+&nbsp;TV streaming services are now available in these countries.
What Happened: The expansion of TMTG into Canada and Mexico comes amidst a global tariff war instigated by Trump. The company&#8217;s Truth+ mobile&nbsp;and TV apps are now&nbsp;available for download in both countries, according to a recent announcement. &#8220;Truth&nbsp;Social and Truth+ are now&nbsp;fully open for business&#8221; in Canada and Mexico, stated&nbsp;Trump Media CEO Devin Nunes.
&#8220;We hope our northern and southern neighbors will enjoy a refuge from Big Tech corporations, monotonous news channels, and woke TV shows and movies,&#8221; Nunes added. 
The Truth+ mobile app is now accessible on iOS and Android devices, while the TV apps can be found on Roku, Apple, Android, and Amazon Fire TV. In addition to these, Trump Media also owns the fintech platform Truth.Fi.
The timing of this expansion coincides with Trump&#8217;s imposition of hefty&nbsp;tariffs on over 60&nbsp;countries, which has led to a global market sell-off. Interestingly, Canada and Mexico were exempted from this list due to a 25% tariff already imposed in February on all goods not covered by the U.S.-Mexico-Canada trade agreement.
SEE ALSO:&nbsp;<a href="https://benzinga.com/tech/25/04/44726879/vietnam-a-hub-for-us-tech-giants-like-apple-and-nvidia-wants-to-talk-trade-after-trump-pauses-46-tariff" target="_blank" rel="noreferrer noopener">Vietnam, A Hub For US Tech Giants Like Apple And Nvidia, Wants To Talk Trade After Trump Pauses 46% Tariff</a>
Why It Matters: The expansion of TMTG into Canada and Mexico is significant, especially against the backdrop of the ongoing global tariff war. This move could be seen as a strategic one, considering that these two countries were exempted from the tariff impositions on &#8216;Liberation Day&#8217; because in February, Trump imposed a 25% tariff on imports from Mexico and Canada, particularly targeting goods not included in the United States-Mexico-Canada Agreement (USMCA)
Furthermore, this development comes on the heels of a surge in Trump Media&#8217;s stock. The company&#8217;s <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44724530/trump-media-stock-soars-hours-after-president-says-its-a-great-time-to-buy-what-you-need-to-know">shares soared</a> following President Trump&#8217;s announcement of a 90-day pause on reciprocal tariffs. ​On Wednesday afternoon, President Trump used his social media platform, Truth Social make this significant announcement.<a href="https://www.theaustralian.com.au/world/china-threatens-to-hit-back-again-as-trumps-new-tariff-hit-hours-away/news-story/49953d38032694d157c3bbd4d875640e?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"></a>
The availability of Truth+ mobile and TV apps in Canada and Mexico could potentially boost the company&#8217;s user base and revenue. This momentum could further propel the company&#8217;s growth in the new markets.
DJT Price Action:&nbsp;<a href="http://benzinga.com/quote/djt?tblci=GiD1tFFNH-r-bulyXzVS-mm-BVNR3nb6Ojb3DSX9l1ZrFSCN1Vcox-6pnqzj16QvMO-ISg" target="_blank" rel="noreferrer noopener">Trump Media shares</a>&nbsp;surged nearly 22% to close at $20.27 on Wednesday, per&nbsp;<a href="http://pro.benzinga.com/?tblci=GiD1tFFNH-r-bulyXzVS-mm-BVNR3nb6Ojb3DSX9l1ZrFSCN1Vcox-6pnqzj16QvMO-ISg" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The stock declined more than 40% over the past year.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44731819/why-the-bitcoin-bull-market-is-back-on-at-93000-glassnode" target="_blank" rel="noreferrer noopener">Why The Bitcoin Bull Market Is Back On At $93,000: Glassnode &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Media (DJT) Expands Into Canada And Mexico Amid Global Tariff Tensions

JMP Securities analyst Andrew Boone reiterates Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) from Market Perform to Market Perform.

Reiteration

GOOGL

JMP Securities Reiterates Market Perform on Alphabetto Market Perform

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy and raises the price target from $45 to $47.

TVTX

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $47

ReShape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) on Wednesday signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their neuromuscular rehabilitation <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">devices in the U.S</a>.
The flagship product, the Stimel-03, was showcased at the American Occupational Therapy Association 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44722857/reshape-lifesciences-partners-with-motion-informatics-to-bring-ai-driven-neurorehabilitation-techn" rel="noreferrer noopener">Annual Conference and Expo</a>.
&#8220;The signing of this agreement with Motion Informatics marks a significant milestone for ReShape as we expand and diversify into rehabilitation technology,&#8221; ReShape CEO Paul F. Hickey said.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44721380/redwire-joins-ispace-us-in-pursuit-of-nasas-26b-lunar-economy-mission" rel="noreferrer noopener">Redwire Joins ispace Tech In Pursuit Of NASA&#8217;s $2.6 Billion Lunar Economy Mission</a>
Stimel-03 is FDA-cleared and commercially available. It&#8217;s a single, patient-responsive platform that helps patients recover from stroke, injury, or surgery.
&#8220;This partnership accelerates Motion Informatics&#8217; U.S. market strategy by combining ReShape Lifesciences&#8217; commercial reach with our differentiated rehabilitation technologies,&#8221; added Gary Sagiv, CEO of Motion Informatics. 
On Monday, ReShape Lifesciences announced 2024 revenue of $8 million, a contraction of 7.7%, or $700,000, compared <a href="https://www.benzinga.com/pressreleases/25/04/g44673681/reshape-lifesciences-reports-year-ended-december-31-2024-financial-results-and-provides-corporate-" target="_blank" rel="noreferrer noopener">to the same period in 2023</a>.
The primary reason for the decrease is due to the introduction of GLP-1 pharmaceuticals within the U.S.
With the introduction of Lap-Band 2.0, the company experienced a slight growth in units sold of 6.5%.
However, sales of the Lap-Band accessories units decreased by 26.4% within the U.S.
Worldwide sales of Lap-Band units decreased by 8.5%, and accessories decreased by 25.9%. The company increased the price of Lap-Band systems, including accessories, which helped revenues not decrease at the same ratio as the decline in unit sales.
Price Action: ReShapestock is up 80.1% at $0.62 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44725000/kkr-outbids-competitors-edges-closer-to-29b-karo-healthcare-takeover-report" target="_blank" rel="noreferrer noopener">KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover</a></li>
</ul>
Image: Shutterstock

Penny Stocks

Health Care

General

RSLS

Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US

Government

Regulations

Politics

White House's Miran Says Need To Get Regulations Out Of The Way So That Companies Can Build Factories Faster; President Trump's Policies Are Working At Keeping Inflation At Bay

Canaccord Genuity analyst Austin Moeller maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Buy and raises the price target from $14.5 to $15.5.

SPIR

Canaccord Genuity Maintains Buy on Spire Global, Raises Price Target to $15.5

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Buy and maintains $3 price target.

PACB

Canaccord Genuity Maintains Buy on Pacific Biosciences, Maintains $3 Price Target

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

CYTK

JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

As of April 10, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul>
<li>On March 4, Wheeler Real Estate IT posted fourth-quarter FFO of $18.48, down from $182.82 in the year-ago period. The company's sales rose to $27.59 million from $26.21 million. The company has a 52-week high of $3,588.00.</li>
<li>RSI Value: 70.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust fell 4.8% to close at $2.37 on Wednesday.</li>
<li>Edge Stock Ratings: 0.39 Momentum score with Value at 36.37. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/whlr"><img loading="lazy" decoding="async" width="487" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62.png" alt="" class="wp-image-865450" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62.png 487w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62-300x116.png 300w" sizes="(max-width: 487px) 100vw, 487px" /></a></figure>
<h3 class="wp-block-heading">Stratus Properties Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRS#NASDAQ">STRS</a>)</h3>
<ul>
<li>On March 28, the company said revenues for 2024 surged to $54.2 million from $17.3 million for 2023. William H. Armstrong III, Chairman of the Board of Directors (Board) and Chief Executive Officer of Stratus, stated, &#8220;Our experienced team continues to successfully execute on our disciplined strategy by delivering on value-enhancing transactions, continuing to advance our development projects and returning capital to stockholders." The company's stock gained around 23% over the past five days and <a href="https://www.benzinga.com/quote/STRS">has a 52-week high</a> of $30.66.</li>
<li>RSI Value: 75.4</li>
<li>STRS Price Action: Shares of Stratus Properties gained 18.1% to close at $20.91 on Wednesday. </li>
</ul>
How do other stocks rank? Get the full <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">BZ Edge Rankings breakdown here</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

STRS

WHLR

Top 2 Real Estate Stocks That May Keep You Up At Night This Month

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) price target from $30 to $39. Wells Fargo analyst Jeff Cantwell upgraded the rating from Underweight to Overweight. Toast shares closed at $34.38 on Wednesday. <a href="https://www.benzinga.com/quote/TOST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim slashed the price target for Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) from $15 to $13. Guggenheim analyst Subbu Nambi maintained a Buy rating. Neogen shares closed at $5.02 on Wednesday. <a href="https://www.benzinga.com/quote/NEOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS lowered BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) price target from $38 to $31. UBS analyst Joseph Spak downgraded the stock from Buy to Neutral. BorgWarner shares closed at $26.89 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/BWA/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities cut the price target for IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) from $263 to $216. Truist Securities analyst Jailendra Singh maintained a Buy rating. IQVIA shares closed at $157.02 on Wednesday. <a href="https://www.benzinga.com/quote/IQV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from $171 to $159. B of A Securities analyst Tim Anderson maintained a Neutral rating. Johnson &amp; Johnson shares closed at $150.97 on Wednesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital slashed Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) price target from $275 to $170. Loop Capital analyst Mark Schappel downgraded the stock from Buy to Hold. Manhattan Associates shares settled at $166.26 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view </a><a href="https://www.benzinga.com/quote/MANH/analyst-ratings">this </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">stock</a>.</li>
<li>Barclays cut ManpowerGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) price target from $55 to $50. Barclays analyst Manav Patnaik upgraded the stock from Underweight to Equal-Weight. ManpowerGroup shares closed at $52.87 on Wednesday. <a href="https://www.benzinga.com/quote/MAN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $265 to $230. Truist Securities analyst Youssef Squali maintained a Buy rating. Amazon shares closed at $191.10 on Wednesday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho cut the price target for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from $4.2 to $3.5. Mizuho analyst Vijay Rakesh maintained a Neutral rating. NIO shares settled at $3.31 on Wednesday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $208 to $185. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Alphabet shares closed at $158.71 on Wednesday. <a href="https://www.benzinga.com/quote/googl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOOGL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png" alt="" class="wp-image-865996" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

MANH

NEOG

TOST

Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday

Contracts

SYNX

Silynxcom Secures New Purchase Order Valued At ~$1.13M From The Israel Defense Forces

Scotiabank analyst Greg McGinniss maintains Americold Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) with a Sector Outperform and lowers the price target from $28 to $24.

COLD

Scotiabank Maintains Sector Outperform on Americold Realty Trust, Lowers Price Target to $24

White House Economic Adviser Miran Says President Is Buying Time To Create Trade Deals; Never Thought That We Were Headed For Meaningful Recession; Need To Get Regulations Out Of The Way So That Companies Can Build Factories Faster

Press Releases

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Earnings

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Comments

Mineralys Therapeutics

Noticias

Últimas noticias sobre Mineralys Therapeutics (NASDAQ:MLYS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL